Underweight and overweight or obesity and associated factors among school-going adolescents in five ASEAN countries, 2015
ConclusionHigh prevalences of underweight and overweight/obesity were identified in ASEAN countries and several correlates were identified which can help to tailor interventions.
Laparra JM Abstract Non-alcoholic fatty liver disease (NAFLD) is indisputably the most widespread liver disease worldwide, leading to a significant increase in patient morbidity, mortality, and health care utilization. The gut microbiota and its genome (microbiome) have emerged as a novel modulator of the immunometabolic processes that NAFLD implies, but microbiota-targeted interventions have resulted both astounding and at the same time unsuccessful. The most relevant alteration appears to be the overgrowth of Gram-negative bacteria, characterized by an increased ratio of Firmicutes to Bacteroidetes, although cu...
AbstractNon ‐alcoholic fatty liver disease (NAFLD) is one of the most common liver disorders worldwide. NAFLD is considered to be the hepatic component of metabolic syndrome because its features are very similar to those of metabolic disorders such as obesity, inflammation, insulin resistance, and type 2 diab etes. It is clear that NAFLD and type 2 diabetes have a close relationship. However, the exact mechanisms underlying the pathogenesis and progression of NAFLD are still incompletely understood1 ‐3).
CONCLUSION: A significant percentage of the American general population is afflicted by BAFLD and these patients tend to have more advanced liver fibrosis. PMID: 31749901 [PubMed]
In conclusion, the information displayed in this review support that the ghrelin system could be an appealing strategy for the treatment of liver disease.
In conclusion, the information displayed in this review support that the ghrelin system could be an appealing strategy for the treatment of liver disease. PMID: 31758299 [PubMed - as supplied by publisher]
Conclusion: The present study demonstrated an association between fibrosis, a finding of worse prognosis in patients with NAFLD, and moderate to severe OSA, regardless of obesity.
Background: Insulin resistance, the primary mechanism of metabolic syndrome, promotes gastric carcinogenesis. Metabolic syndrome is associated with sarcopenia. We aimed to investigate the association between sarcopenia and gastric carcinogenesis, including precancerous conditions such as atrophic gastritis (AG), intestinal metaplasia (IM), and dysplasia.Methods: The study included adult patients who underwent gastroduodenoscopy at a checkup center. AG and IM were evaluated using endoscopy. Based on muscle mass, sarcopenia was defined as a skeletal muscle index
Publication date: Available online 17 October 2019Source: Trends in Endocrinology &MetabolismAuthor(s): Daniela Stols-Gonçalves, G. Kees Hovingh, Max Nieuwdorp, Adriaan G. HolleboomThe prevalence of non-alcoholic fatty liver disease (NAFLD) is strongly increasing and may put patients at increased risk for atherosclerotic cardiovascular disease (asCVD). Both disease phenotypes often co-occur, in the case of obesity, insulin resistance, diabetes mellitus type 2, and the metabolic syndrome. We explore the pathogenesis of NAFLD, the epidemiology of asCVD in NAFLD patients, shared drivers of both phenotypes, and fact...
Albiflorin (AF) is a small molecule (MW 481) isolated from Paeoniae radix, a plant used as a remedy for various conditions with pathogenesis shared by metabolic diseases. Reported here is our characterization of its therapeutic profiles in three mouse models with distinctive pathological features of metabolic syndrome (MetS). Our results firstly showed that AF alleviated high fat (HF) induced obesity and associated glucose intolerance, suggesting its therapeutic efficacy for MetS. In the type 2 diabetes (T2D) model induced by a combination of HF and low doses of streptozotocin, AF lowered hyperglycaemia and improved insuli...
DiscussionThe final results of study will be analyzed and disseminated in 2020.Trial registrationClinicalTrials.gov, ID:NCT03467282. Registered on 15 March 2018.